Immupharma (IMM) RNS Announcements

Add to Alert list
Date Time Source Announcement
16 Apr 2021 04:36 PM
RNS
Price Monitoring Extension
25 Feb 2021 04:41 PM
RNS
Second Price Monitoring Extn
25 Feb 2021 04:35 PM
RNS
Price Monitoring Extension
09 Feb 2021 07:00 AM
RNS
Update- scheduled Phase 3 trials in lupus patients
18 Jan 2021 07:00 AM
RNS
Appointment of Company Secretary
04 Jan 2021 07:00 AM
RNS
Holding(s) in Company
02 Dec 2020 07:00 AM
RNS
IMM TO PRESENT AT BIOTECH SHOWCASE DIGITAL 2021
30 Nov 2020 07:00 AM
RNS
Total Share Capital Notification
26 Nov 2020 07:00 AM
RNS
Grant of Share Options & PDMR dealing
24 Nov 2020 07:00 AM
RNS
Conversion of Convertible Security
23 Nov 2020 07:00 AM
RNS
Conversion of Convertible Security
20 Nov 2020 07:00 AM
RNS
Update : FDA confirms 4 Dec for Type 'A' meeting
18 Nov 2020 07:00 AM
RNS
Total Share Capital Notification - Replacement
10 Nov 2020 07:00 AM
RNS
Update on submission to the FDA
30 Sep 2020 07:01 AM
RNS
Total Share Capital Notification
30 Sep 2020 07:00 AM
RNS
Interim Results
29 Sep 2020 07:00 AM
RNS
Share Subscription into Incanthera plc
22 Sep 2020 07:00 AM
RNS
Repayment of Convertible Security
11 Sep 2020 07:59 AM
RNS
Update on submission to the FDA
10 Sep 2020 10:59 AM
RNS
Conversion of Convertible Security
09 Sep 2020 01:45 PM
RNS
Conversion of Convertible Security
08 Sep 2020 03:49 PM
RNS
Holding(s) in Company
08 Sep 2020 09:00 AM
RNS
Director/PDMR Shareholding / TR -1
07 Sep 2020 07:02 AM
RNS
Placing - update; related party transaction)
03 Sep 2020 07:00 AM
RNS
Conversion of Convertible Security
02 Sep 2020 07:00 AM
RNS
Placing to raise £6.5 million
01 Sep 2020 07:00 AM
RNS
Holding(s) in Company
27 Jul 2020 07:00 AM
RNS
FDA submission for Special Protocol Assessment
18 Jun 2020 11:31 AM
RNS
2020 AGM - ALL RESOLUTIONS PASSED
16 Jun 2020 07:00 AM
RNS
Total Share Capital Notification
11 Jun 2020 12:00 PM
RNS
TR-1 Notification of major holdings
11 Jun 2020 07:00 AM
RNS
STRAT. INVTS FROM 2 SPECIALIST US H'CARE INVESTORS
05 Jun 2020 07:00 AM
RNS
Change of Registered Office Address
02 Jun 2020 07:00 AM
RNS
Notification of Change of AGM Venue
21 May 2020 07:00 AM
RNS
Notice of AGM and posting of Report & Accounts
18 May 2020 01:45 PM
RNS
TR-1: Notification of major holdings
14 May 2020 07:00 AM
RNS
Efforts in fight vs Covid-19 with Lupuzor; Ureka
30 Apr 2020 09:57 AM
RNS
Audited Report & Accounts published on website
30 Apr 2020 07:00 AM
RNS
FINAL RESULTS FOR THE 12M ENDED 31/12/19
06 Apr 2020 07:00 AM
RNS
IMM live on Investor Meet Company platform 7 April
03 Apr 2020 03:55 PM
RNS
Holding(s) in Company
02 Apr 2020 08:26 AM
RNS
Holding(s) in Company
31 Mar 2020 04:41 PM
RNS
Second Price Monitoring Extn
31 Mar 2020 04:37 PM
RNS
Price Monitoring Extension
31 Mar 2020 12:07 PM
RNS
Second Price Monitoring Extn
31 Mar 2020 12:02 PM
RNS
Price Monitoring Extension
30 Mar 2020 08:02 AM
RNS
£1.5m Subscrip'n to fund R&D pipeline- replacement
30 Mar 2020 07:00 AM
RNS
£1.5m Subscription to fund R&D pipeline expansion
20 Mar 2020 04:45 PM
RNS
Second Price Monitoring Extn
20 Mar 2020 04:40 PM
RNS
Price Monitoring Extension

ImmuPharma is a pharma company headquartered in London with its research R&D team, ImmuPharma Biotech, based in France. 

ImmuPharma listed on AIM under the ticker IMM. 

IMM research strategy is based on two strategic axes: research based on external collaboration aimed at discovering new active ingredients, which has led to the development of our most advanced project in terms of clinical development: P140 an active peptide against the auto-immune disease, Lupus SLE and internal research based on the use of molecular programming technologies, which has notably led to the development of the BioAMB and BioCIN projects.

IMM share price listed in London at 1,190p in 2000. 

UK 100

Latest directors dealings